JP2016516719A5 - - Google Patents

Download PDF

Info

Publication number
JP2016516719A5
JP2016516719A5 JP2016502840A JP2016502840A JP2016516719A5 JP 2016516719 A5 JP2016516719 A5 JP 2016516719A5 JP 2016502840 A JP2016502840 A JP 2016502840A JP 2016502840 A JP2016502840 A JP 2016502840A JP 2016516719 A5 JP2016516719 A5 JP 2016516719A5
Authority
JP
Japan
Prior art keywords
arg
phe
cys
trp
cyclo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016502840A
Other languages
English (en)
Japanese (ja)
Other versions
JP6622690B2 (ja
JP2016516719A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/028590 external-priority patent/WO2014144260A1/en
Publication of JP2016516719A publication Critical patent/JP2016516719A/ja
Publication of JP2016516719A5 publication Critical patent/JP2016516719A5/ja
Application granted granted Critical
Publication of JP6622690B2 publication Critical patent/JP6622690B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016502840A 2013-03-15 2014-03-14 ペプチド組成物 Active JP6622690B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361790469P 2013-03-15 2013-03-15
US61/790,469 2013-03-15
PCT/US2014/028590 WO2014144260A1 (en) 2013-03-15 2014-03-14 Peptide compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019113626A Division JP7046871B2 (ja) 2013-03-15 2019-06-19 ペプチド組成物

Publications (3)

Publication Number Publication Date
JP2016516719A JP2016516719A (ja) 2016-06-09
JP2016516719A5 true JP2016516719A5 (cg-RX-API-DMAC7.html) 2017-06-22
JP6622690B2 JP6622690B2 (ja) 2019-12-18

Family

ID=50588892

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016502840A Active JP6622690B2 (ja) 2013-03-15 2014-03-14 ペプチド組成物
JP2019113626A Active JP7046871B2 (ja) 2013-03-15 2019-06-19 ペプチド組成物
JP2022048719A Active JP7654587B2 (ja) 2013-03-15 2022-03-24 ペプチド組成物
JP2025045947A Pending JP2025102830A (ja) 2013-03-15 2025-03-19 ペプチド組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019113626A Active JP7046871B2 (ja) 2013-03-15 2019-06-19 ペプチド組成物
JP2022048719A Active JP7654587B2 (ja) 2013-03-15 2022-03-24 ペプチド組成物
JP2025045947A Pending JP2025102830A (ja) 2013-03-15 2025-03-19 ペプチド組成物

Country Status (10)

Country Link
US (4) US10196425B2 (cg-RX-API-DMAC7.html)
EP (2) EP2970388B1 (cg-RX-API-DMAC7.html)
JP (4) JP6622690B2 (cg-RX-API-DMAC7.html)
CN (3) CN105492456B (cg-RX-API-DMAC7.html)
AU (5) AU2014227712B2 (cg-RX-API-DMAC7.html)
CA (1) CA2906694A1 (cg-RX-API-DMAC7.html)
ES (1) ES2693761T3 (cg-RX-API-DMAC7.html)
RU (2) RU2020120797A (cg-RX-API-DMAC7.html)
TR (1) TR201815173T4 (cg-RX-API-DMAC7.html)
WO (1) WO2014144260A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3539551T (pt) 2011-12-29 2021-11-04 Rhythm Pharmaceuticals Inc Método de tratamento de distúrbios associados ao recetor de melanocortina-4 em portadores heterozigóticos
CA3209602A1 (en) 2013-03-15 2014-09-18 Rhythm Pharmaceuticals, Inc. Pharmaceutical compositions
RU2020120797A (ru) * 2013-03-15 2020-07-02 Ритм Фармасьютикалз, Инк. Пептидные композиции
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
AU2016330773A1 (en) * 2015-09-30 2018-04-19 Charité-Universitätsmedizin Berlin Method of treating melanocortin-4 receptor pathway-associated disorders
CN109803979B (zh) * 2016-10-04 2023-01-31 帝斯曼知识产权资产管理有限公司 黑皮质素-1-受体激动剂
CN111032680A (zh) * 2017-03-15 2020-04-17 诺和诺德股份有限公司 能够与黑皮质素4受体结合的双环化合物
WO2019195756A1 (en) 2018-04-06 2019-10-10 Rhythm Pharmaceuticals, Inc. Compositions for treating kidney disease
WO2020053414A1 (en) * 2018-09-14 2020-03-19 Novo Nordisk A/S Bicyclic compounds capable of acting as melanocortin 4 receptor agonists
CA3192873A1 (en) * 2020-09-24 2022-03-31 Leonardus H.T. Van Der Ploeg Methods of treating melanocortin-4 receptor pathway-associated disorders
CN113332416B (zh) * 2021-05-17 2022-02-22 宁波大学 丙谷二肽在制备治疗非酒精性脂肪肝药物中的应用
CN113209270B (zh) * 2021-05-17 2022-02-22 宁波大学 丙谷二肽在制备防治急性肝衰竭药物中的应用
CN116789802A (zh) * 2023-06-25 2023-09-22 湖北省农业科学院畜牧兽医研究所 一种山羊mc4r增强型突变体及其应用
WO2025131101A1 (zh) * 2023-12-22 2025-06-26 上海多米瑞生物技术有限公司 多肽化合物、其药物组合物及其用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0292291B1 (en) * 1987-05-22 1994-08-10 University Patents, Inc. Linear and cyclic analogs of alpha-msh fragments with extraordinary potency
US5731408A (en) * 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
GB9827500D0 (en) * 1998-12-14 1999-02-10 Wapharm Ab Compounds for control of eating, growth and body weight
US7176279B2 (en) * 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
WO2003006620A2 (en) * 2001-07-11 2003-01-23 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
MXPA03001721A (es) * 2000-08-30 2003-05-27 Hoffmann La Roche Peptidos ciclicos selectivos.
US7342089B2 (en) * 2001-07-11 2008-03-11 Palatin Technologies, Inc. Cyclic peptides for treatment for cachexia
US7345144B2 (en) * 2001-07-11 2008-03-18 Palatin Technologies, Inc. Cyclic peptides for treatment of cachexia
US7034004B2 (en) * 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
FR2851563B1 (fr) 2003-02-26 2005-04-22 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
FR2852957B1 (fr) 2003-03-31 2005-06-10 Sod Conseils Rech Applic Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament
US20060293223A1 (en) * 2003-06-19 2006-12-28 Eli Lilly And Company Patent Division Uses of melanocortin-3 receptor (mc3r) agonist peptides
EP1644023A2 (en) * 2003-06-19 2006-04-12 Eli Lilly And Company Melanocortin recptor 4(mc4) agonists and their uses
FR2862971B1 (fr) 2003-11-28 2006-03-24 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
US8343031B2 (en) * 2004-03-23 2013-01-01 Michael Gertner Obesity treatment systems
FR2872165B1 (fr) 2004-06-24 2006-09-22 Sod Conseils Rech Applic Nouveaux derives de pyrimido-benzimidazole
CN101528250A (zh) 2005-07-08 2009-09-09 研究及应用科学协会股份有限公司 黑皮质素受体的配体
CN105837661B (zh) * 2005-07-08 2024-10-15 益普生制药股份有限公司 黑皮质素受体配体
EP2148692B1 (en) * 2007-05-25 2017-01-25 Ipsen Pharma S.A.S. Melanocortin receptor ligands modified with hydantoin
US20100173834A1 (en) 2007-06-15 2010-07-08 Zheng Xin Dong Cyclic peptide melanocortin receptor ligands
RU2453328C2 (ru) 2007-11-05 2012-06-20 Ипсен Фарма С.А.С. Применение меланокортинов для лечения чувствительности к инсулину
WO2009151383A1 (en) * 2008-06-09 2009-12-17 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for the treatment of obesity and other diseases associated with melanocortin receptor function
NZ596617A (en) * 2009-06-08 2014-04-30 Palatin Technologies Inc Melanocortin receptor-specific peptides
UY32690A (es) * 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
EP2461681A4 (en) * 2009-08-05 2013-04-24 Ipsen Pharma Sas USE OF MELANOCORTINS FOR TREATING DYSLIPIDEMIA
US20120226018A1 (en) 2009-11-16 2012-09-06 Ipsen Pharma, S.A.S. Process for the Synthesis of Ac-Arg-Cyclo(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2
ES2654147T3 (es) 2009-11-16 2018-02-12 Ipsen Pharma S.A.S. Composiciones farmacéuticas de ligandos del receptor de melanocortina
EP2720684B1 (en) 2011-06-14 2019-01-16 Ipsen Pharma S.A.S. A sustained-release composition containing peptides as the active ingredient
EP2705835A1 (en) 2012-06-08 2014-03-12 Ipsen Pharma S.A.S. Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
RU2020120797A (ru) * 2013-03-15 2020-07-02 Ритм Фармасьютикалз, Инк. Пептидные композиции
CA3209602A1 (en) * 2013-03-15 2014-09-18 Rhythm Pharmaceuticals, Inc. Pharmaceutical compositions

Similar Documents

Publication Publication Date Title
JP2016516719A5 (cg-RX-API-DMAC7.html)
RU2015145593A (ru) Пептидные композиции
HRP20240998T1 (hr) T stanični receptori
CA2777758C (en) Peptidic glp-2 agonists
JP2012512903A5 (cg-RX-API-DMAC7.html)
AU2014313779B2 (en) Amino diacids containing peptide modifiers
KR102812908B1 (ko) 인크레틴 유사체의 제조 방법
IL308831A (en) T cell receptors
EP1914310A2 (en) Cell-permeable peptide inhibitors of the JNK signal transduction pathway
CN116082455A (zh) 白细胞介素-23受体的肽抑制剂及其用于治疗炎症性疾病的用途
AU2004232314B2 (en) Peptide vectors
RU2016101711A (ru) Высокостабильный т-клеточный рецептор и способ его получения и применения
JP2017502024A5 (cg-RX-API-DMAC7.html)
BR112014027345A2 (pt) análogos de peptídeo 2 semelhante ao glucagon (glp-2)
JP2016518351A5 (cg-RX-API-DMAC7.html)
JP2019503340A5 (cg-RX-API-DMAC7.html)
RS54722B1 (sr) Agonisti v1a receptora
CN110678550A (zh) 长效肾上腺髓质素衍生物
JP6798883B2 (ja) 生物学的活性なインスリン誘導体
JP2018507854A5 (cg-RX-API-DMAC7.html)
BR112015024583B1 (pt) Composto, suas composições e seu uso para a produção de um medicamento para o tratamento de câncer
HK1111730A (en) Cell-permeable peptide inhibitors of the jnk signal transduction pathway